Catalent, wholly owned by Novo Holdings, is a leading global CDMO that possesses the expertise to support product development, launch, and full production supply. Their wide range of services includes viral vector production for gene-enabled cell therapies, autologous cell therapy, and allogeneic cell therapy development. Catalent's teams have worked with a broad range of viral systems, including lentivirus, retrovirus, and adeno-associated viruses. The emphasis in adeno-associated virus therapies has awarded Catalent the opportunity to work with more than 20 gene therapy companies over the years and assist in their clinical and commercial development efforts.
